Around 4,000 British people are diagnosed each year with multiple myeloma, an aggressive cancer that affects a type of white blood cell in the bone marrow called plasma cells. Average survival after diagnosis is just three to five years, despite patients receiving intensive treatment with a combination of drugs.
All common treatment regimens for multiple myeloma also contain at least one drug with the side-effect of peripheral neuropathy – a disorder of the nervous system that can cause altered sensation, tingling, numbness and severe pain.
Almost one-third of patients in this study who were treated with the immune stimulating therapy thalidomide developed neuropathy, along with around one-third of patients whose treatment regimen contained the chemotherapy drug vincristine. In contrast, only 6.4 per cent of patients whose treatment combination did not include thalidomide or vincristine developed neuropathy.
Symptoms sometimes clear when the patient stops the treatment or reduces their dose, but neuropathy can be permanent and crippling, and until now it has not been possible to predict which patients will be afflicted.
In this study*, the researchers analysed DNA from around 1,500 patients with multiple myeloma, searching through almost 1,000 genes that have previously been linked with cancer growth and treatment response.
When they examined patients who had been treated with thalidomide, they found five regions of DNA were more common in patients who had suffered neuropathy than those who had not developed the condition. Interestingly, the regions are part of genes involved in repair, development and inflammation of the peripheral nervous system.
To determine whether the genes found were drug-specific, they ran the same scan on patients treated with vincristine and found a different set of genes – nine in total – were more common in patients who developed neuropathy. The finding indicates that each drug type causes neuropathy through a different biological pathway.
The study raises the possibility patients could have their blood screened for neuropathy risk genes.
“Doctors could use this simple and useful test to identify patients at high risk of neuropathy,” the ICR’s Professor Gareth Morgan, who is also Head of the Haematology Unit at The Royal Marsden Hospital NHS Foundation Trust, says. “At-risk patients could be closely monitored, and potentially given alternative treatments, lower doses or additional therapy to reduce side-effects. This knowledge may also help us develop treatments that could protect patients from neuropathy.”
This study also has implications for other cancer types as vincristine, for example, is commonly used to treat acute lymphoblastic leukaemia and lymphoma.
The study was funded by the Medical Research Council (MRC), International Myeloma Foundation, Myeloma UK and the National Institute for Health Research through its support of the Biomedical Research Centre at The Royal Marsden and the ICR.
Media Contact: Science Communications Manager Jane Bunce on email@example.com or 0207 153 5106 or after hours 077217 47900.
Notes to editors:
* The study was a new arm of the MRC Myeloma-IX trial, which compared standard treatment with thalidomide-containing regiments. The trial included 970 patients treated with cyclophosphamide, thalidomide and dexamethasone (CTD) and 550 patients treated with cyclophosphamide, vincistine, doxorubicin and dexamethasone. The results were validated in a second comparable study, the HOVON-50/GMMG-HD3 trial.
“Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma” publishes in the Journal of Clinical Oncology on March 1 2011, with an accompanying editorial “Genetic Predisposition for Chemotherapy-Induced Neuropathy in Multiple Myeloma” by Pamela S. Becker, University of Washington.
The Institute of Cancer Research (ICR)
- The ICR is Europe’s leading cancer research centre.
- The ICR has been ranked the UK’s top academic research centre, based on the results of the Higher Education Funding Council’s Research Assessment Exercise.
- The ICR works closely with partner The Royal Marsden NHS Foundation Trust to ensure patients immediately benefit from new research. Together the two organisations form the largest comprehensive cancer centre in Europe.
- The ICR has charitable status and relies on voluntary income, spending 90 pence in every pound of total income directly on research.
- As a college of the University of London, the ICR also provides postgraduate higher education of international distinction.
- Over its 100-year history, the ICR’s achievements include identifying the potential link between smoking and lung cancer which was subsequently confirmed, discovering that DNA damage is the basic cause of cancer and isolating more cancer-related genes than any other organisation in the world.
- The ICR is home to the world’s leading academic cancer drug development team. Several important anti-cancer drugs used worldwide were synthesised at the ICR and it has discovered an average of two preclinical candidates each year over the past five years.
For more information visit www.icr.ac.uk
The Royal Marsden Hospital
The Royal Marsden was the first hospital in the world dedicated to cancer diagnosis, treatment and research into the causes of cancer. Today, as The Royal Marsden NHS Foundation Trust, together with its academic partner The Institute of Cancer Research, form the largest comprehensive cancer centre in Europe with over 40,000 patients from the UK and abroad seen each year. It is a centre of excellence, and was the only NHS Trust to achieve the highest possible ranking in the Healthcare Commission’s Annual Health Check for four year in a row. Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.
For further information please contact Naomi Owen on 0207 808 2107 or email firstname.lastname@example.org
Medical Research Council
For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including one of the first antibiotics penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century.